Journal of Neural Transmission

, Volume 113, Issue 1, pp 59–73 | Cite as

Serotonergic mechanisms in Parkinson’s disease: opposing results from preclinical and clinical data

  • B. Scholtissen
  • F. R. J. Verhey
  • H. W. M. Steinbusch
  • A. F. G. Leentjens
Review

Summary.

Parkinson’s disease (PD) is a neuropsychiatric disease affecting approximately 1–2% of the general population. The classical triad of symptoms, tremor, rigidity, and bradykinesia is mainly caused by degeneration of dopaminergic neurons from the substantia nigra. However, other neurotransmitter systems also show signs of degeneration, among which the serotonergic system. The exact role of serotonin in PD remains unclear. We present here a review about functional serotonergic interventions and serotonergic imaging studies in PD, and will go into the importance of combining preclinical and clinical research data in order to gain more insight into the role of serotonin in PD. More specifically, the present review is aimed at bridging the gap between data from animal models of PD and data from human research.

Keywords: Parkinson’s disease, serotonin, functional intervention. 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aberg-Wistedt, A, Hasselmark, L, Stain-Malmgren, R, Aperia, B, Kjellman, BF, Mathe, AA 1998Serotonergic ‘vulnerability’ in affective disorder: a study of the tryptophan depletion test and relationships between peripheral and central serotonin indexes in citalopram-responders.Acta Psychiatr Scand97374380PubMedCrossRefGoogle Scholar
  2. Adams RD, Victor M (1993) Priciples of neurology. McGraw-Hill, New YorkGoogle Scholar
  3. Arai, R, Karasawa, N, Nagatsu, I 1996Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study.Brain Res706177179PubMedCrossRefGoogle Scholar
  4. Avila, A, Cardona, X, Martin-Baranera, M, Maho, P, Sastre, F, Bello, J 2003Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial.J Clin Psychopharmacol23509513PubMedCrossRefGoogle Scholar
  5. Baeken, C, D’Haenen, H, Flamen, P, Mertens, J, Terriere, D, Chavatte, K, Boumon, R, Bossuyt, A 1998123I-5-I-R91150, a new single-photon emission tomography ligand for 5-HT2A receptors: influence of age and gender in healthy subjects.Eur J Nucl Med2516171622PubMedCrossRefGoogle Scholar
  6. Balcioglu, A, Zhang, K, Tarazi, FI 2003Dopamine depletion abolishes apomorphine- and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: a microdialysis study.Neuroscience11910451053PubMedCrossRefGoogle Scholar
  7. Beasley, BL, Davenport, RW, Chase, TN 1977Fenfluramine hydrochloride treatment of parkinsonism.Arch Neurol34255256PubMedGoogle Scholar
  8. Benloucif, S, Galloway, MP 1991Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis.Eur J Pharmacol20018PubMedCrossRefGoogle Scholar
  9. Benloucif, S, Keegan, MJ, Galloway, MP 1993Serotonin-facilitated dopamine release in vivo: pharmacological characterization.J Pharmacol Exp Ther265373377PubMedGoogle Scholar
  10. Birkmayer, W, Birkmayer, JD 1987Dopamine action and disorders of neurotransmitter balance.Gerontology33168171PubMedCrossRefGoogle Scholar
  11. Birkmayer, W, Danielczyk, W, Neumayer, E, Riederer, P 1972The balance of biogenic amines as condition for normal behaviour.J Neural Transm33163178PubMedCrossRefGoogle Scholar
  12. Birkmayer W, Riederer P (1985) Biochemische Veranderungen bei der Parkinson-Krankheit. In: Birkmayer W, Riederer P (eds) Die Parkinson-Krankheit. Biochemie, Klinik, Therapie. Springer, Wien New York, pp 29–59Google Scholar
  13. Bishop, C, Walker, PD 2003Combined intrastriatal dopamine d1 and serotonin 5-ht2 receptor stimulation reveals a mechanism for hyperlocomotion in 6-hydroxydopamine-lesioned rats.Neuroscience121649657PubMedCrossRefGoogle Scholar
  14. Brucke, T, Kornhuber, J, Angelberger, P, Asenbaum, S, Frassine, H, Podreka, I 1993SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT. Binding kinetics in the human brain.J Neural Transm94137146CrossRefGoogle Scholar
  15. Bryant, RC 1980Duration of illness and response to tryptophan in Parkinson’s disease.Arch Neurol37677PubMedGoogle Scholar
  16. Busatto, GF, Pilowsky, LS, Costa, DC, Mertens, J, Terriere, D, Ell, PJ, Mulligan, R, Travis, MJ, Leysen, JE, Lui, D, Gacinovic, S, Waddington, W, Lingford-Hughes, A, Kerwin, RW 1997Initial evaluation of 123I-5-I-R91150, a selective 5-HT2A ligand for single-photon emission tomography, in healthy human subjects.Eur J Nucl Med24119124PubMedCrossRefGoogle Scholar
  17. Canter, GJ, De La Torre, R, Mier, M 1961A method for evaluating disability in patients with Parkinson’s disease.J Nerv Ment Dis133143147PubMedCrossRefGoogle Scholar
  18. Chase, TN 1972Serotonergic mechanisms in Parkinson’s disease.Arch Neurol27354356PubMedGoogle Scholar
  19. Chase, TN 1974Serotonergic mechanisms and extrapyramidal function in man.Adv Neurol53139PubMedGoogle Scholar
  20. Chase, TN, Ng, LK, Watanabe, AM 1972Parkinson’s disease. Modification by 5-hydroxytryptophan.Neurology22479484PubMedGoogle Scholar
  21. Chen, CP, Alder, JT, Bray, L, Kingsbury, AE, Francis, PT, Foster, OJ 1998Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson’s disease neocortex.Ann NY Acad Sci861288289PubMedCrossRefGoogle Scholar
  22. Cleare, AJ, Murray, RM, O’Keane, V 1998Assessment of serotonergic function in major depression using d-fenfluramine: relation to clinical variables and antidepressant response.Biol Psychiatry44555561PubMedCrossRefGoogle Scholar
  23. Coppen, A, Metcalfe, M, Carroll, JD, Morris, JG 1972Levodopa and L-tryptophan therapy in Parkinsonism.Lancet1654658PubMedCrossRefGoogle Scholar
  24. Cummings, JL 1992Depression and Parkinson’s disease: a review.Am J Psychiatry149443454PubMedGoogle Scholar
  25. Dauer, W, Przedborksi, S 2003Parkinson’s disease: mechanisms and models.Neuron39889909PubMedCrossRefGoogle Scholar
  26. De Deurwaerdere, P, Navailles, S, Berg, KA, Clarke, WP, Spampinato, U 2004Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens.J Neurosci2432353241PubMedCrossRefGoogle Scholar
  27. Delgado, PL, Charney, DS, Price, LH, Aghajanian, GK, Landis, H, Heninger, GR 1990Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan.Arch Gen Psychiatry47411418PubMedGoogle Scholar
  28. Delgado, PL, Charney, DS, Price, LH, Landis, H, Heninger, GR 1989Neuroendocrine and behavioral effects of dietary tryptophan depletion in healthy subjects.Life Sci4523232332PubMedCrossRefGoogle Scholar
  29. Deumens, R, Blokland, A, Prickaerts, J 2002Modeling Parkinson’s disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway.Exp Neurol175303317PubMedCrossRefGoogle Scholar
  30. Di Giovanni, G, De Deurwaerdere, P, Di Mascio, M, Di Matteo, V, Esposito, E, Spampinato, U 1999Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study.Neuroscience91587597PubMedCrossRefGoogle Scholar
  31. Di Matteo, V, Cacchio, M, Di Giulio, C, Esposito, E 2002Role of serotonin(2C) receptors in the control of brain dopaminergic function.Pharmacol Biochem Behav71727734PubMedCrossRefGoogle Scholar
  32. Di Matteo, V, De Blasi, A, Di Giulio, C, Esposito, E 2001Role of 5-HT(2C) receptors in the control of central dopamine function.Trends Pharmacol Sci22229232PubMedCrossRefGoogle Scholar
  33. Doder, M, Rabiner, EA, Turjanski, N, Lees, AJ, Brooks, DJ 2003Tremor in Parkinson’s disease and serotonergic dysfunction: an 11C-WAY 100635 PET study.Neurology60601605PubMedGoogle Scholar
  34. Fernstrom, JD, Wurtman, RJ, Hammarstrom-Wiklund, B, Rand, WM, Munro, HN, Davidson, CS 1979Diurnal variations in plasma concentrations of tryptophan, tryosine, and other neutral amino acids: effect of dietary protein intake.Am J Clin Nutr3219121922PubMedGoogle Scholar
  35. Fox, SH, Brotchie, JM 20005-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat.Eur J Pharmacol3985964PubMedCrossRefGoogle Scholar
  36. Fox, SH, Moser, B, Brotchie, JM 1998Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease.Exp Neurol1513549PubMedCrossRefGoogle Scholar
  37. Frechilla, D, Cobreros, A, Saldise, L, Moratalla, R, Insausti, R, Luquin, M, Del Rio, J 2001Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys.Synapse39288296PubMedCrossRefGoogle Scholar
  38. Fuller, RW 1977Fenfluramine and Parkinson’s disease.Arch Neurol34720PubMedGoogle Scholar
  39. Gaspar, P, Febvret, A, Colombo, J 1993Serotonergic sprouting in primate MTP-induced hemiparkinsonism.Exp Brain Res96100106PubMedGoogle Scholar
  40. Gerber, R, Altar, CA, Liebman, JM 1988Rotational behavior induced by 8-hydroxy-DPAT, a putative 5HT-1A agonist, in 6-hydroxydopamine-lesioned rats.Psychopharmacology (Berl)94178182CrossRefGoogle Scholar
  41. Gobert, A, Rivet, JM, Lejeune, F, Newman-Tancredi, A, Adhumeau-Auclair, A, Nicolas, JP, Cistarelli, L, Melon, C, Millan, MJ 2000Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat.Synapse36205221PubMedCrossRefGoogle Scholar
  42. Haapaniemi, TH, Ahonen, A, Torniainen, P, Sotaniemi, KA, Myllyla, VV 2001[123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients.Mov Disord16124130PubMedCrossRefGoogle Scholar
  43. Hall, CD, Weiss, EA, Morris, CE, Prange, AJ,Jr 1972Rapid deterioration in patients with parkinsonism following tryptophan-pyridoxine administration.Neurology22231237PubMedGoogle Scholar
  44. Henderson, J, Yiannikas, C, Graham, JS 1992Effect of ritanserin, a higly selective 5-HT2 receptor antagonist, on Parkinson’s disease.Clin Exp Neurol29277282PubMedGoogle Scholar
  45. Hildebrand, J, Delecluse, F 1987Effect of ritanserin, a selective serotonin-S2 antagonist, on Parkinson’s rest tremor.Cur Ther Res41298300Google Scholar
  46. Hornykiewicz, O 1986Parkinson’s disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms.Adv Neurol60140147Google Scholar
  47. Hornykiewicz, O 1998Biochemical aspects of Parkinson’s disease.Neurology51S2S9PubMedGoogle Scholar
  48. Iravani, MM, Jackson, MJ, Kuoppamaki, M, Smith, LA, Jenner, P 20033,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.J Neurosci2391079115PubMedGoogle Scholar
  49. Jacobs, BL, Fornal, CA 19935-HT and motor control: a hypothesis.Trends Neurosci16346352PubMedCrossRefGoogle Scholar
  50. Kent, JM, Coplan, JD, Martinez, J, Karmally, W, Papp, LA, Gorman, JM 1996Ventilatory effects of tryptophan depletion in panic disorder: a preliminary report.Psychiatry Res648390PubMedCrossRefGoogle Scholar
  51. Kerenyi, L, Ricaurte, GA, Schretlen, DJ, McCann, U, Varga, J, Mathews, WB, Ravert, HT, Dannals, RF, Hilton, J, Wong, DF, Szabo, Z 2003Positron emission tomography of striatal serotonin transporters in Parkinson disease.Arch Neurol6012231229PubMedCrossRefGoogle Scholar
  52. Kim, SE, Choi, JY, Choe, YS, Choi, Y, Lee, WY 2003Serotonin transporters in the midbrain of Parkinson’s disease patients: a study with 123I-beta-CIT SPECT.J Nucl Med44870876PubMedGoogle Scholar
  53. Kim, SE, Lee, WY, Choe, YS, Kim, JH 1999SPECT measurement of iodine-123-beta-CIT binding to dopamine and serotonin transporters in Parkinson’s disease: correlation with symptom severity.Neurol Res21255261PubMedGoogle Scholar
  54. Klaassen, T, Klumperbeek, J, Deutz, NE, van Praag, HM, Griez, E 1998Effects of tryptophan depletion on anxiety and on panic provoked by carbon dioxide challenge.Psychiatry Res77167174PubMedCrossRefGoogle Scholar
  55. Klaassen, T, Riedel, WJ, van Someren, A, Deutz, NE, Honig, A, van Praag, HM 1999Mood effects of 24-hour tryptophan depletion in healthy first-degree relatives of patients with affective disorders.Biol Psychiatry46489497PubMedCrossRefGoogle Scholar
  56. Klawans, HL, Ringel, SP 1973A clinical study of methysergide in Parkinsonism: evidence against a serotonergic mechanism.J Neurol Sci19399405PubMedCrossRefGoogle Scholar
  57. Knobelman, DA, Kung, HF, Lucki, I 2000Regulation of extracellular concentrations of 5-hydroxytryptamine (5-HT) in mouse striatum by 5-HT(1A) and 5-HT(1B) receptors.J Pharmacol Exp Ther29211111117PubMedGoogle Scholar
  58. Kostic, VS, Lecic, D, Doder, M, Marinkovic, J, Filipovic, S 1996Prolactin and cortisol responses to fenfluramine in Parkinson’s disease.Biol Psychiatry40769775PubMedCrossRefGoogle Scholar
  59. Langston, JW, Ballard, P, Tetrud, JW, Irwin, I 1983Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.Science219979980PubMedCrossRefGoogle Scholar
  60. Laprade, N, Radja, F, Reader, TA, Soghomonian, JJ 1996Dopamine receptor agonists regulate levels of the serotonin 5-HT2A receptor and its mRNA in a subpopulation of rat striatal neurons.J Neurosci1637273736PubMedGoogle Scholar
  61. Lavoie, B, Parent, A 1990Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey.J Comp Neurol299116PubMedCrossRefGoogle Scholar
  62. Lebsanft, HB, Mayerhofer, A, Kovar, KA, Schmidt, WJ 2003Is the Ecstasy-induced ipsilateral rotation in 6-hydroxydopamine unilaterally lesioned rats dopamine independent?J Neural Transm110707718PubMedGoogle Scholar
  63. Leentjens, AF 2004Depression in Parkinson’s disease: conceptual issues and clinical challenges.J Geriatr Psychiatry Neurol17120126PubMedCrossRefGoogle Scholar
  64. Leentjens AFG (2002) Parkinson’s disease, depression, and serotonin. Maastricht University, MaastrichtGoogle Scholar
  65. Lehmann, J 1973Tryptophan malabsorption in levodopa-treated parkinsonian patients. Effect of tryptophan on mental disturbances.Acta Med Scand194181189PubMedGoogle Scholar
  66. LeMarquand, DG, Pihl, RO, Young, SN, Tremblay, RE, Seguin, JR, Palmour, RM, Benkelfat, C 1998Tryptophan depletion, executive functions, and disinhibition in aggressive, adolescent males.Neuropsychopharmacology19333341PubMedCrossRefGoogle Scholar
  67. Lucas, G, Bonhomme, N, De Deurwaerdere, P, Le Moal, M, Spampinato, U 19978-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release.Psychopharmacology (Berl)1315763CrossRefGoogle Scholar
  68. Lucas, G, De Deurwaerdere, P, Caccia, S, Umberto, S 2000The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo: opposite role of 5-HT(2A) and 5-HT(2C) receptor subtypes and significance of the haloperidol dose used.Neuropharmacology3910531063PubMedCrossRefGoogle Scholar
  69. Lucas, G, Spampinato, U 2000Role of striatal serotonin2a and serotonin2c receptor subtypes in the control of in vivo dopamine outflow in the rat striatum.J Neurochem74693701PubMedCrossRefGoogle Scholar
  70. Maeda, T, Kannari, K, Shen, H, Arai, A, Tomiyama, M, Matsunaga, M, Suda, T 2003Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation.Neurosci Lett3431720PubMedCrossRefGoogle Scholar
  71. Mayeux, R 1990The “serotonin hypothesis” for depression in Parkinson’s disease.Adv Neurol53163166PubMedGoogle Scholar
  72. Mayeux, R, Stern, Y, Cote, L, Williams, JB 1984Altered serotonin metabolism in depressed patients with parkinson’s disease.Neurology34642646PubMedGoogle Scholar
  73. McCance-Katz, EF, Marek, KM, Price, LH 1992Serotonergic dysfunction in depression associated with Parkinson’s disease.Neurology4218131814PubMedGoogle Scholar
  74. McNaught, KS, Perl, DP, Brownell, AL, Olanow, CW 2004Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease.Ann Neurol56149162PubMedCrossRefGoogle Scholar
  75. Mignon, L, Wolf, WA 2002Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat.Psychopharmacology (Berl)1638594CrossRefGoogle Scholar
  76. Miyawaki, E, Meah, Y, Koller, WC 1997Serotonin, dopamine, and motor effects in Parkinson’s disease.Clin Neuropharmacol20300310PubMedCrossRefGoogle Scholar
  77. Murai, T, Muller, U, Werheid, K, Sorger, D, Reuter, M, Becker, T, von Cramon, DY, Barthel, H 2001In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson’s disease.J Neuropsychiatry Clin Neurosci13222228PubMedGoogle Scholar
  78. Navailles, S, De Deurwaerdere, P, Porras, G, Spampinato, U 2004In vivo evidence that 5-HT2C receptor antagonist but not agonist modulates cocaine-induced dopamine outflow in the rat nucleus accumbens and striatum.Neuropsychopharmacology29319326PubMedCrossRefGoogle Scholar
  79. Neumeyer, JL, Wang, SY, Milius, RA, Baldwin, RM, Zea-Ponce, Y, Hoffer, PB, Sybirska, E, al-Tikriti, M, Charney, DS, Malison, RT,  et al. 1991[123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain.J Med Chem3431443146PubMedCrossRefGoogle Scholar
  80. Newman, ME, Shapira, B, Lerer, B 1998Evaluation of central serotonergic function in affective and related disorders by the fenfluramine challenge test: a critical review.Int J Neuropsychopharmcol14969PubMedCrossRefGoogle Scholar
  81. Nicholson, SL, Brotchie, JM 20025-hydroxytryptamine (5-HT, serotonin) and Parkinson’s disease – opportunities for novel therapeutics to reduce the problems of levodopa therapy.Eur J Neurol916PubMedCrossRefGoogle Scholar
  82. Numan, S, Lundgren, KH, Wright, DE, Herman, JP, Seroogy, KB 1995Increased expression of 5HT2 receptor mRNA in rat striatum following 6-OHDA lesions of the adult nigrostriatal pathway.Brain Res Mol Brain Res29391396PubMedCrossRefGoogle Scholar
  83. Oh, JD, Bibbiani, F, Chase, TN 2002Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.Exp Neurol177557564PubMedCrossRefGoogle Scholar
  84. Orth, M, Tabrizi, SJ 2003Models of Parkinson’s disease.Mov Disord18729737PubMedCrossRefGoogle Scholar
  85. Park, SB, Coull, JT, McShane, RH, Young, AH, Sahakian, BJ, Robbins, TW, Cowen, PJ 1994Tryptophan depletion in normal volunteers produces selective impairments in learning and memory.Neuropharmacology33575588PubMedCrossRefGoogle Scholar
  86. Rabey, JM, Vardi, J, Askenazi, JJ, Streifler, M 1977L-tryptophan administration in L-dopa-induced hallucinations in elderly Parkinsonian patients.Gerontology23438444PubMedCrossRefGoogle Scholar
  87. Riedel, WJ, Klaassen, T, Deutz, NE, van Someren, A, van Praag, HM 1999Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation.Psychopharmacology (Berl)141362369CrossRefGoogle Scholar
  88. Sandyk, R, Fisher, H 1989L-tryptophan supplementation in Parkinson’s disease.Int J Neurosci45215219PubMedCrossRefGoogle Scholar
  89. Scatton, B, Javoy-Agid, F, Rouquier, L, Dubois, B, Agid, Y 1983Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson’s disease.Brain Res275321328PubMedCrossRefGoogle Scholar
  90. Schmidt, CJ, Fadayel, GM, Sullivan, CK, Taylor, VL 19925-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine.Eur J Pharmacol2236574PubMedCrossRefGoogle Scholar
  91. Schmitt, JA, Jorissen, BL, Sobczak, S, van Boxtel, MP, Hogervorst, E, Deutz, NE, Riedel, WJ 2000Tryptophan depletion impairs memory consolidation but improves focussed attention in healthy young volunteers.J Psychopharmacol142129PubMedCrossRefGoogle Scholar
  92. Sempere, AP, Duarte, J, Cabezas, C, Claveria, LE, Coria, F 1995Aggravation of parkinsonian tremor by cisapride.Clin Neuropharmacol187678PubMedCrossRefGoogle Scholar
  93. Sobczak, S, Honig, A, Nicolson, NA, Riedel, WJ 2002Effects of acute tryptophan depletion on mood and cortisol release in first-degree relatives of type I and type II bipolar patients and healthy matched controls.Neuropsychopharmacology27834842PubMedCrossRefGoogle Scholar
  94. Tanaka, H, Kannari, K, Maeda, T, Tomiyama, M, Suda, T, Matsunaga, M 1999Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats.Neuroreport10631634PubMedCrossRefGoogle Scholar
  95. Ungerstedt, U 19686-Hydroxy-dopamine induced degeneration of central monoamine neurons.Eur J Pharmacol5107110PubMedCrossRefGoogle Scholar
  96. Van Kroonenburgh, MJ, Leentjens, AFG, Verhey, FRJ, Vreeling, F, Troost, J 2001Imaging of 5-HT2a receptors in Parkinson’s disease.J Nucl Med42227Google Scholar
  97. Van Praag, HM, De Haan, S 1979Central serotonin metabolism and frequency of depression.Psychiatry Res1219224PubMedCrossRefGoogle Scholar
  98. Volpi, R, Caffarra, P, Boni, S, Scaglioni, A, Malvezzi, L, Saginario, A, Chiodera, P, Coiro, V 1997ACTH/cortisol involvement in the serotonergic disorder affecting the parkinsonian brain.Neuropsychobiology357378PubMedCrossRefGoogle Scholar
  99. Volpi, R, Caffarra, P, Scaglioni, A, Boni, S, Saginario, A, Chiodera, P, Coiro, V 1997Defective 5-HT 1-receptor-mediated neurotransmission in the control of growth hormone secretion in Parkinson’s disease.Neuropsychobiology357983PubMedCrossRefGoogle Scholar
  100. Zhou, FC, Bledsoe, S, Murphy, J 1991Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain.Brain Res556108116PubMedCrossRefGoogle Scholar
  101. Zoldan, J, Friedberg, G, Livneh, M, Melamed, E 1995Psychosis in advanced Parkinson’s disease: treatment with ondansetron, a 5-HT3 receptor antagonist.Neurology4513051308PubMedGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2005

Authors and Affiliations

  • B. Scholtissen
    • 1
  • F. R. J. Verhey
    • 1
  • H. W. M. Steinbusch
    • 1
  • A. F. G. Leentjens
    • 1
  1. 1.Department of Psychiatry and NeuropsychologyInstitute of Brain and Behaviour, Maastricht UniversityMaastrichtThe Netherlands

Personalised recommendations